Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
The Vertical Group
AddedFeb 13, 2024
UpdatedJun 28, 2026
The Vertical Group

The Vertical Group

Operating

Vertical Group L.P.: A US-based venture capital firm specializing in medical technology and biotechnology.

Location
Basking Ridge, NJ, US
Founded
1988
Firm
Compare
Portfolio
Employees
Website

Investments

Route 92 Medical
Route 92 Medical

Total Raised

$171.5M

Rounds

7

Series F$31MNovember 2023
Series E$56MDecember 2021
Series A$5.9MMay 2016
Luminopia
Luminopia

Total Raised

$33.1M

Rounds

5

Series A$16MJune 2023
Seed$5.7MNovember 2022
MicroTransponder
MicroTransponder

Total Raised

$115.1M

Rounds

12

Series E$73MJune 2022
Carlsmed
Carlsmed

Total Raised

$44.5M

Rounds

6

Series B$30MApril 2022
Series A$10MDecember 2020
Hinge Health
Hinge Health
Secondary Market

Total Raised

$1B

Rounds

10

Series A$8.3MJuly 2017
Seed$1.3MJune 2016
Home Dialysis Plus
Home Dialysis Plus
Acquired

Total Raised

$318.5M

Rounds

4

Series C$76.5MMay 2017
Outset Medical
Outset Medical
Public

Total Raised

$927M

Rounds

11

Series C$76.5MMay 2017
Debt Financing$45MJune 2015
Series B$60MMay 2015
Suture Concepts
Suture Concepts

Total Raised

$6.4M

Rounds

4

Series D$1MDecember 2015
Series D$3.8MDecember 2014
Series C$1MAugust 2011
Seed$500kApril 2006
Monteris Medical
Monteris Medical

Total Raised

$216.1M

Rounds

18

Series B$30MNovember 2014
Omada Health
Omada Health

Total Raised

$528.5M

Rounds

11

Series B$23MApril 2014
Series A$4.7MMarch 2013
Flexuspine
Flexuspine

Total Raised

$3.2M

Rounds

3

Series B$2.1MNovember 2011
PhotoThera
PhotoThera

Total Raised

$101M

Rounds

4

Series D$50MMay 2009
Elron Ventures
Elron Ventures

Total Raised

$52M

Rounds

2

Post Ipo Equity$52MDecember 2006
ViaCyte
ViaCyte
Public

Total Raised

$235.5M

Rounds

15

Series Unknown$20MMay 2006